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Abstract 
 
 
Study Objective: To study fasting serum Homocysteine level as a prognostic 
marker in patients with alcoholic liver cirrhosis and viral cirrhosis, comparing 
the homocysteine level with MELD score and Child-Turcotte-Pugh scores. 
Design and Setting: Prospective study, Govt. Peripheral Hospital, Anna 
nagar, Chennai. 
Patients: Fifty alcoholic cirrhosis and 15 viral cirrhosis patients. 
Study period: Between December 2009 and April 2011. 
Results: Serum homocysteine levels are seen elevated in 41 out of 50 (82%) 
alcoholic cirrhosis patients compared to 1 out of 15 (6.67%) viral cirrhosis 
patients. The serum homocysteine level in alcoholic group is 23.4 + 7.91 
μmol/L compared to 10.05 + 2.75 μmol/L in viral cirrhosis group. The ‘p’ 
value for variation in serum homocysteine level corresponding to both CTP 
and MELD scores is < 0.0001, in both alcoholic and viral cirrhosis patients. 
Conclusion: Serum homocysteine levels are elevated in alcoholic cirrhosis 
than in viral cirrhosis and correlate well with CTP and MELD scores in 
alcoholic cirrhosis patients. 
Keywords: Homocysteine, Cirrhosis, MELD and Child-Turcotte-Pugh score. 
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INTRODUCTION 
 
Liver plays a central role in the synthesis and metabolism of homocysteine, 
given the fact that dietary methionine is predominantly metabolized in the 
liver. It is well known that serum homocysteine level increases in non 
alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis 
(NASH) patients. Recent studies have shown that serum homocysteine levels 
are elevated in chronic alcoholism and liver cirrhosis patients also. 
Homocysteine is a well known nerve and vascular endothelial toxin, 
promoting mortality, coronary atherosclerosis, myocardial infarction, stroke, 
and dementia. Recently it is found that homocysteine can induce liver 
diseases also, by promoting hepatic fibrogenesis.  
Homocysteine metabolism requires cofactors of vitamins folate, B12 and 
pyridoxine, but the metabolism of these vitamins is impaired in cirrhotic 
patients. Homocysteine regulators called methyl donors are required to reduce 
serum homocysteine level. Methylation is a vital part of many biochemical 
processes in the body involving DNA, proteins and lipids. As improper 
methylation affects the brain and nervous system, correcting 
hyperhomocysteinemia will improve mental and emotional health as well. 
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Though several studies have proved hyperhomocysteinemia in alcoholic liver 
disease and stressed the importance of reducing the serum homocysteine 
level, there are only very few studies which compared the serum level of 
homocysteine with the severity of liver disease. This study is undertaken to 
compare the degree of elevation of serum homocysteine level with severity of 
liver disease in alcoholic and viral cirrhotics and to know whether serum 
homocysteine level can be used as a prognostic marker to assess the severity 
of liver disease. 
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REVIEW OF LITERATURE 
Homocysteine 
Homocysteine is a homologue of the amino acid cysteine, with the formula 
HSCH2CH2CH(NH2)CO2H, not obtained from the diet, instead, bio-
synthesized from the essential amino acid methionine (Selhub 1999), that 
inflicts damage to the inner arterial lining (endothelium) by degrading the 
structural proteins of arteries and other cells of the body. Methionine is found 
abundantly in meat, seafood, dairy products and egg. Vegetables with few 
exceptions (sesame seeds and Brazil nuts) are low in methionine. Even such 
protein rich legumes as beans, peas and lentils contain relatively small 
amount of methionine compared to animal derived foods. Homocysteine 
exists in several forms and the sum of all homocysteine forms is called total 
homocysteine. It is biosynthesized from methionine by the removal of its 
terminal C8 methyl group. First, methionine receives an adenosine group 
from ATP, a reaction catalyzed by S-adenosyl-methionine synthetase, to give 
S-adenosyl methionine (SAM). SAM then transfers the methyl group to an 
acceptor molecule, (i.e., norepinephrine as an acceptor during epinephrine 
synthesis, DNA methyltransferase as an intermediate acceptor in the process 
of DNA methylation). The adenosine is then hydrolyzed to yield L-
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homocysteine. L-Homocysteine has two primary fates: conversion via 
tetrahydrofolate (THF) back into L-methionine or conversion to L-cysteine 
(Champe et al., 2008). Homocysteine can be recycled into methionine or 
converted into cysteine with the aid of B-vitamins. Hyperhomocysteinemia 
irrespective of its cause is an independent risk factor for stroke, coronary and 
peripheral arterial diseases (Russo et al., 2004). The effects of Homocysteine 
on collagen also impact the protein matrix of bone. It is converted to either L-
methionine or L-cysteine. This occurs in a multi step process requiring certain 
B-vitamins. The B-vitamins (N5-methyl tetrahydrofolate, and B12) and the 
enzyme 5,10-methylene tetrahydrofolate reductase are needed to complete 
this process. When the B-vitamins folic acid, pyridoxine and 
cyanocobalamine are lacking in the system, the homocysteine cannot be 
converted properly, which causes high homocysteine levels to build up in the 
body (Millet et al., 1994).  
Many clinical testing laboratories consider a homocysteine value between 5 
and 15 micromol / litre as healthy (Ueland PM, et al; 1993). However, studies 
indicate that adults with homocysteine values more than 6.3 micromol per 
litre are at increased risk of atherosclerosis, heart attack and stroke. After age 
50, a more practical value for homocysteine is 7 to 8 micromol per litre. Life 
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extension foundation also recommends the target values for homocysteine as 
7 to 8 micromol per litre.  
Raised homocysteine levels have also been linked to 
• Stroke  
• Vascular Disease  
• Liver Disease  
• Kidney Disease  
• Thyroid diseases  
• Alzheimer’s disease and dementia  
• Depression  
• Erectile dysfunction  
• Eye disease 
• Hearing loss 
Causes of hyperhomocysteinemia 
• Increasing age  
• Consuming a lot of coffee or alcohol  
• Smoking 
• Eating large amounts of red meat or chicken  
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• Gene expression – MTHFR Gene or “poor methylation gene” 
• Levadopa - medication for Parkinson’s Disease  
• Antiepileptic medications - used for preventing seizures  
• Niacin (B-vitamin) - used for lowering cholesterol  
• Methotrexate - used for treating inflammatory diseases  
• Fenofibrate - used for lowering cholesterol  
• Metformin - used for treating diabetes ((Desouza, et al; 2002) 
• Nitrous oxide – used in anaesthesia 
• Pyrimethamine – antihelminthic 
• Sulfasalazine – used in inflammatory bowel disease 
• Intense prolonged physical exercise (Van Meurs et al., 2004) 
• Diabetes 
• Renal failure 
• Hypothyroidism 
• Malabsorptive conditions 
• Inflammatory bowel disease 
Methods of lowering homocysteine level 
Dietary intake of folate, vitamin B12 and vitamin B6 are the chief nutritional 
determinants of blood homocysteine concentrations, with folate being the 
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predominant vitamin. N5-formyl tetrahydrofolate is the important methyl 
donor in our body. Methylation is a vital part of many biochemical processes 
in the body. Methylation becomes impaired, as we get older. Supplementation 
with B- vitamins folic acid, pyridoxine and cyanocobalamine will reduce the 
serum homocysteine level (Van Guldener and Stehouwer 2001: Melinda 
2006). Following are the methods to be adopted for lowering serum 
homocysteine level: 
• Reduce homocysteine accumulation  
• Increase homocysteine “re-methylation”  
• Routine blood tests to check homocysteine levels  
• Screening to test for genetic defects that cause high levels  
• Addressing symptoms associated with elevated homocysteine such as: 
o High blood pressure  
o Diabetes  
o Coronary artery disease 
o Low thyroid function 
Serum homocysteine level can be reduced by avoiding methionine rich diet, 
particularly the non vegetarian food items, avoiding smoking, coffee intake 
and alcohol, doing regular physical exercise and weight reducing. 
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Alternatively homocysteine reduction can be achieved by intake of 5-methyl 
tetrahydrofolate, natural folate or folic acid tablets, N-Acetyl cysteine 600 to 
1800 mg daily, SAMe (S-Adenosyl methionine) 400 mg two to four times 
daily, taurine 1000 to 3000 mg daily, trimethyl glycine 2000 to 6000 mg 
daily, vitamin B12 (Cobalamin) 1 to 2 mg daily, vitamin B2 (Riboflavin) 10 
to 100 mg daily, vitamin B6 (as pyridoxal phosphate) 100 to 200 mg daily, 
zinc 30 to 60 mg daily, micronized creatine 500 mg four to eight times daily, 
omega-3- polyunsaturated fatty acid rich fish oil or Choline 250 to 500 mg 
daily. 
Methionine metabolism 
 
Nearly one half of the daily intake of methionine is metabolized in the liver. 
Methionine is first metabolized to S-Adenosyl methionine (SAM) catalysed 
by the enzyme methionine adenosyl transferase MAT1A in the liver and in 
other tissues by MAT2A. S-Adenosyl methionine (SAM) functions as the 
principal biological methyl donor through several transmethylation pathways, 
as the precursor of aminopropyl groups used in polyamine biosynthesis and as 
a precursor of glutathione through its conversion to cysteine along the 
transsulfuration pathway. Under normal conditions, most of the generated 
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SAM is used in transmethylations reactions through methyl transferases, in 
which methyl groups are donated to al large number of molecules including 
DNA, RNA, biogenic amines, phospholipids, histones and other proteins. 
Methylation of these compounds may modulate cellular functions and 
integrity. In this process, the S-Adenosyl methionine is converted to S-
Adenosyl homocysteine (SAH), which is a potent competitive inhibitor of 
most methyl transferases. Both an increase in SAH and a decrease in SAM / 
SAH ratio are known to inhibit transmethylation reactions(Purohit et al., 
2007). 
 
S-Adenosyl methionine also decreased lipopolysaccharide(LPS) stimulated 
tumor necrosis factor (TNF) release and increases interleukin-10 (IL-10) 
release in a monocyte cell line, supporting the concept that SAM may have 
direct hepatoprotective function and may modify LPS stimulated cytokine 
production. 
 
In the kidney and liver, homocysteine is remethylated by the enzyme betaine 
homocysteine methyltransferase which transfers a methyl group to 
homocysteine via the demethylation of betaine to dimethylglycine. Folic acid 
can also play a critical role in the regeneration of homocysteine to methionine 
by means of 5-methyltetrahydrofolate(5-MTHF). Fatty liver develops in mice 
 10 
that lack the gene for MTHF reductase supporting the role of this critical 
pathway in the development of hepatic steatosis and steatohepatitis. The 
transulfuration pathway requires the enzyme cystathionine synthase and 
vitamin B6. Once formed from cystathionine, cysteine can be utilized in 
protein synthesis and glutathione production. Alterations in plasma 
homocysteine and liver SAM and SAH contents in precirrhotic stages and in 
secondary biliary cirrhosis have been demonstrated in experimental animals 
(Mohammed R et al., 2005). 
 
NAFLD 
 
The prevalence of NAFLD varies from 10 to 24% in the general population, 
thus making it the most common liver disease in the world. Fatty liver has 
been documented in 8 to 10% of normal population and 70 to 80% of obese 
individuals. More than 20% of potential liver donors have NAFLD. 
Correspondingly NASH occurs in 3% of general population and 20% of 
morbidly obese individuals. Non alcoholic fatty liver disease which was 
characterized by the association of fatty liver and lobular hepatitis and 
chronically elevated plasma levels of alanine aminotransferase (ALT) in 
patients with negligible intake or absence of alcohol was first identified by 
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Ludwig et al in 1980. Insulin sensitivity of adipocytes depends on profile of 
adipokines- TNF-ά, leptin, adipokinin, plasminogen activator inhibitor-1, sex 
hormone, fatty acids, resistin and cortisol. Fundamental defect in NAFLD 
seem to be the insulin resistance that leads to impairment in insulin mediated 
suppression of lipolysis. Net result is increased release of free fatty acids from 
the adipose tissue. Increased uptake of fatty acids by hepatocytes leads to 
mitochondrial β oxidation overload, with consequent accumulation of fatty 
acids within hepatocytes. If degree of free fatty acid delivery and 
reesterification to triglyceride overwhelms ability to form and export VLDL, 
triglycerides accumulate in the liver. FFA decreases insulin mediated glucose 
disposal in skeletal muscle and also in liver, it induces gluconeogenesis 
pathways and inhibits glucose utilization. This leads to increased peripheral 
glucose level, which in turn leads to hyperinsulinemia. Hyperinsulinemia 
increases the synthesis of fatty acids in hepatocytes by increasing glycolysis 
and increases accumulation of triglyceride by decreasing hepatic production 
of apolipoprotein B-100. Thus insulin resistance leads to accumulation of fat 
in hepatocytes by two mechanisms: peripheral lipolysis and hyperinsulinemia. 
Related to this hypothesis, obesity which gives rise to insulin resistance, 
hypertriglyceridemia and leptin resistance are thought to play an important 
role (Harrison, et al., 2002).  The final common pathway for development of 
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steatohepatitis is oxidative stress within hepatocytes. The redox state is 
determined by balance between pro-oxidant and antioxidant processes. 
Oxidative stress results from generation of reactive oxygen species and 
deficiency of antioxidant defenses. Multiple metabolic pathways like 
mitochondrial, peroxisomal, cytochrome P-450, NADPH oxidase, 
cyclooxygenase and lipooxygenase pathways, lead to oxidative stress. 
Mitochondrial reactive oxygen species deplete hepatic antioxidants and allow 
accumulation of more reactive oxygen species. Depletion of antioxidants like 
paraoxonase – 1 may enhance hepatic damage in steatosis. The Kupffer cell 
dysfunction induced by insulin resistance leads to increased phagocytic 
activity, decreased anti-inflammatory IL-10, thus leading to increased 
necroinflammatory activity. Also liver regeneration is impaired in fatty 
hepatocytes. Stellate cell activation occurs via noncytokine pathways or via 
cytokine pathways (TNF-ά). TNF-ά stimulates secretion of profibrogenic 
cytokines like IL-6, TGF-β and PDGF. Leptin secreted by activated stellate 
cells further leads to TGF-β production. NAFLD has the potential to progress 
to fibrosis, cirrhosis, terminal liver failure and hepatocellular carcinoma 
(Sheth, et al., 1997).  
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Hyperhomocysteinemia has been found in patients with type 1 and type 2 
diabetes mellitus associated with premature atherosclerosis (Hoffmann MA, 
Hoogeveen EK, et al., 1998). Several observations suggest that there might be 
some links between insulin resistance and hyperhomocysteinemia (Sanchez-
Margalet V, Meigs JB, et al., 2002). Homocysteine is an atherogenic and 
thrombogenic risk factor and may be involved in hepatic fibrosis (Torres L, et 
al., 1999). In a large study conducted at Turkey in 2007, serum homocysteine 
levels were significantly elevated (13.44 + 3.1 μmol/L) in NAFLD patients 
when compared to healthy controls (8.62 + 1.34 μmol/L) with p value of 
0.015 (Ali cetinkaya, et al., 2007).  
 
Cirrhosis of liver 
The word "cirrhosis" derives from Greek κιρρός [kirrhós] meaning yellowish, 
tawny (the orange-yellow colour of the diseased liver) + English medical 
suffix -osis. While the clinical entity was known before, it was René Laennec 
who gave it the name "cirrhosis" in his 1819.  Cirrhosis is a consequence of 
chronic liver disease characterized by replacement of liver tissue by fibrosis, 
scar tissue and regenerative nodules leading to loss of liver function. Cirrhosis 
is most commonly caused by alcoholism, hepatitis B and C, metabolic 
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diseases and fatty liver disease, but has many other possible causes. Cirrhosis 
of liver is associated with several metabolic disturbances in our body. Ascites 
is the most common complication of cirrhosis, and is associated with a poor 
quality of life, increased risk of infection, and a poor long-term outcome. 
Other potentially life-threatening complications are portal hypertension, 
bleeding from esophageal varices, hepatic encephalopathy, hepatorenal 
syndrome, hepatopulmonary syndrome and hepatocellular carcinoma. 
Cirrhosis is generally irreversible, and treatment usually focuses on 
preventing progression and complications. In advanced stages of cirrhosis the 
only option is a liver transplant. 
Pathogenesis of alcoholic liver disease 
 
One of the early targets of ethanol toxicity is mitochondrial fatty acid 
oxidation. Alcohol metabolism alters the NADH/NAD redox potential in the 
liver, which in turn impairs the β-oxidation and tricarboxylic acid cycle 
activity. Chronic alcohol consumption can increase fatty acid synthesis in 
humans. Gut derived endotoxin, including toxic lipopolysaccharide may 
trigger both cytokine release and oxidative stress. In the liver, endotoxin 
activates Kupffer cells, which play a major role in liver inflammation by 
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releasing reactive oxygen species and cytokines. Patients with alcoholic liver 
disease have increased levels of proinflammatory cytokines IL-1, IL-6 and 
TNF-ά as well as the chemokinesIL-8 and other cytokines. 
 
Alcohol induces oxidative stress in the liver by either enhancing the 
production of reactive oxygen species and / or decreasing the level of 
endogenous antioxidants. The sources of reactive oxygen species include 
mitochondria, cytochrome P-450 2E1 in hepatocytes, NADPH oxidase in 
inflammatory cells and activated Kupffer cells. 
 
Acetaldehyde is the most important metabolite of ethanol leading to liver 
damage. The toxicity of acetaldehyde is due to its capacity to form adducts 
with intracellular proteins which can trigger an abnormal immune response 
characterized by the production of antibodies directed against acetaldehyde 
epitopes. Adiponectin and TNF-ά suppress each other’s action in their target 
tissues. Chronic ethanol intake decreases circulating concentrations of 
adiponectin and reduced adiponectin expression. Transforming growth factor- 
β is a key profibrotic cytokine. Acetaldehyde stimulates the production of 
several extracellular matrix proteins including type 1 collagen and enhances 
the expression of TGF-β1 in hepatic stellate cells and fibroblasts.  
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Pathogenesis of viral cirrhosis in HBV 
Hepatitis B virus is generally not a cytopathic virus, and the severity of HBV 
associated liver disease is considered to be related to the intensity of the host 
immunologic response to the virus. The cellular immune response appears to 
be the arm principally involved in the pathogenesis of disease. The 
immunologic response to HBV encompasses both an innate or nonspecific 
response (for example, natural killer cells and interferons) and an adaptive 
immune response, including antibodies to viral antigens, human leukocyte 
antigen (HLA) class II restricted CD4+ T cells, and HLA class I restricted 
CD8+ CTLs. Induction of the antigen specific T cell response is thought to 
occur in lymphoid organs and results in the maturation and expansion of T 
cells that are specific for these viral epitopes and is followed by their 
migration to the liver, where they perform their effector function. 
 
During acute HBV infection, most HBV DNA molecules are cleared rapidly 
from the liver via noncytopathic mechanisms mediated by cytokines that are 
released initially by cells of the innate immune system and later by liver 
infiltrating HBV specific CD8+ cells. Cell mediated immune responses are 
efficient in self limited infection because the responses are vigorous, 
multispecific and oriented toward type 1 helper (Th1) cells. Persons with 
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chronic HBV infection, by contrast, exhibit infrequent, narrowly focused and 
weak HBV specific T cell responses. In chronic hepatitis B, the mononuclear 
cells in liver infiltrates of patients with chronic hepatitis B at any given time 
are non antigen specific.  
 
CD8+ CTLs are thought to contribute to the disease process in the liver and 
result in apoptosis of infected hepatocytes. To be recognized by the CD8+ 
CTLs, targeted hepatocytes must present viral epitopes as short peptides that 
have been endogenously processed and fit within the peptide-binding groove 
of the class I major histocompatiblity complex (MHC) molecules. The 
binding of the CTL T cell receptor (TCR) to the peptide-MHC complex on 
the hepatocyte surface can then result in the direct killing of the infected cell 
and release of potent antiviral cytokines by the activated CTL. Recognition by 
MHC class II restricted CD4+ helper T cells requires the appropriate 
presentation of viral peptides in the context of class II MHC molecules. The 
CD4+ cells produce antiviral cytokines and provide help in neutralizing 
antibody production. 
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Pathogenesis of viral cirrhosis in HCV 
 
In chronically infected patients, the pathogenesis of liver damage is largely 
immune mediated. In a small subset of immunocompromised HCV infected 
patients among both HIV infected patients and organ transplant recipients, 
however, a syndrome termed fibrosing cholestatic hepatitis develops. Such 
cases are thought to result from direct viral hepatotoxicity of infected cells, 
because viral levels are typically greater than 30 million copies / mL and 
hepatocytes contain enormous concentrations of virus and viral proteins. 
 
HCV infection elicits an immune response in the host that involves both an 
initial innate response as well as a subsequent adaptive response. The innate 
response is the first line of defense against the virus and includes several arms 
such as natural killer cell activation and cellular antiviral mechanisms 
triggered by pathogen associated molecular patterns (PAMPs) recognized by 
the cell. These processes can lead to apoptosis of infected cells within the first 
few hours of infection. Natural killer cells, as the effector cells of the innate 
immune system, also produce tumor necrosis factor (TNF-β) and interferon-ά, 
cytokines that are critical for dendritic cell maturation and subsequent 
induction of adaptive immunity. After this, however, the virus initiates a 
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number of mechanisms that undermine the ability of the host to control the 
infection.  
 
Virus related disruption of the innate and later adaptive immune responses 
occur at several levels. NK cell function is slowed possibly because NK-cell 
mediated cytotoxicity and production of cytokines are interrupted when the 
HCV E2 protein binds its cellular receptor CD81. HCV - NS5A and E2 both 
can disrupt protein kinase R (PKR) function to suppress translation, thereby 
allowing viral replication to continue. In addition, NS5A inhibits 2’-5’-
oligoadenylate synthetase. The ability of HCV to impair the innate immune 
response prevents development of a vigorous adaptive immune response to 
the infection. NK cells do not adequately activate dentritic cells, and as a 
result, the priming of CD8+ and CD4+ T cells in HCV infected patients is 
inadequate.  
 
HCV specific T cells are enriched at the site of viral replication, with an 
increased number in the liver when compared with the peripheral blood. 
CD8+ lymphocytes predominate, suggesting that cytotoxic T lymphocytes are 
the main perpetrators of hepato cellular injury. The T cell immune response in 
the liver may result in direct lysis of infected cells and inhibition of viral 
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replication by secreted antiviral cytokines. Antibodies to viral proteins are 
produced in low levels and do not appear to correlate with the stage of 
infection or immune reactivity. In summary, viral products play an integral 
role in the immune regulation that leads to chronic infection instead of viral 
clearance. Both the virus and the immune response probably play a role in the 
development of hepatocellular injury. 
 
Methionine metabolism in alcoholic liver disease 
 
Chronic administration of ethanol in experimental animals increases levels of 
plasma homocysteine, reduces liver S-Adenosyl methionine and increases S-
Adenosyl homocysteine. Acetaldehyde induced inhibition of methionine 
synthase activity is associated with increased activity of betaine homocysteine 
methyl transferase, which uses betaine as a substrate to methylate 
homocysteine to methionine and dimethyl glycine. Reactive oxygen species 
generated by ethanol metabolism impair the expression of methionine 
adenosyl transferase with consequent reduced levels of S-Adenosyl 
methionine (Purohit et al., 2007). Since SAM is a precursor of glutathione, 
deficiency of SAM will result in glutathione deficiency which is observed in 
many forms of liver disease. Hepatic deficiency of MAT may be caused in 
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part by glutathione deficiency as glutathione is required for optimal 
expression of MAT activity in liver. Also hepatic MAT is sensitive to 
oxidative stress, and the subnormal hepatic MAT activity in patients with 
alcoholic liver disease could result from oxidation of MAT. Depletion of 
mitochondrial glutathione is thought to be one pathogenic factor in the 
development of alcoholic liver disease and S-Adenosyl methionine prevents 
depletion of glutathione in mitochondriae in experimental alcoholic liver 
disease. In alcoholic liver disease, serum SAM, the universal substrate for 
methyl transferase reactions is decreased, while levels of S-Adenosyl 
homocysteine (SAH), an inhibitor of methylation are decreased, and serum 
homocysteine are elevated. SAH is also a substrate for the bidirectional 
enzyme SAH hydrolase that can both regenerate homocysteine or can 
enhance levels of S-Adenosyl homocysteine when homocysteine level is 
elevated (Kharbanda KK, et al; 2009). Homocysteine is mainly reduced 
through the transsulfuration pathway that includes two vitamin B6 dependant 
enzymes, cystathionine-β-synthase and γ- cystathionase, ultimately producing 
the antioxidant glutathione. Since S-Adenosyl methionine facilitates the 
cystathionine-β-synthase reaction, reduced liver SAM levels are associated 
with decreased production of glutathione. Reduced SAM and elevated SAH 
predictably reduce the potential for methylation reactions, potentially 
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contributing to the activation of many genes relevant to liver injury 
(Esfandiari F, et al; 2010). Ethanol-induced increases in hepatic SAH also 
potentiate pro-inflammatory cytokine TNF-ά and cell death in ethanol-fed 
mice (Song Z, et al; 2004).  Homocysteine is postulated to play a role in the 
pathogenesis of fatty liver and in experimental animals the reduction of 
homocysteine level by administration of betaine results in attenuating the 
severity of alcoholic liver disease. Deficiency of B vitamins B6, B12 and folic 
acid in alcoholics also lead to impaired metabolism of methionine and 
impaired regeneration of homocysteine and finally fatty changes in the liver. 
The correlation between serum cystathionine level with the severity of liver 
fibrosis point to the importance of the homocysteine transsulfuration pathway 
in alcoholic liver disease and may have important diagnostic and therapeutic 
implications (Valentina Medici, et al; 2010). In ethanol-fed micro pigs, folate 
deficiency amplified abnormal hepatic methionine metabolism, increased 
oxidative stress and DNA damage and promoted early development of 
alcoholic liver damage. In smooth muscle cells and in liver stellate cells, 
homocysteine impairs extra cellular matrix breakdown, by inducing the 
expression and synthesis of the tissue inhibitor of metalloproteinases-1 
(TIMP-1) and alpha 1-procollagen (Garcia-Tevijano ER, et al; 2001). 
Alcohol-induced hyperhomocysteinemia in mice, is associated with 
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endoplasmic reticulum stress, leading to the activation of apoptotic and fat 
synthetic gene expression in the liver, that contribute to some of the 
pathologic features of alcoholic liver disease. The correction of 
hyperhomocysteinemia by betaine reverts these changes (Ji C, et al; 2003). 
 
Effect of folate level on Homocysteine 
 
Folate deficiency disturbs hepatic methionine metabolism and causes 
impaired catabolism of homocysteine in the liver and other tissues, decreasing 
cystathionine, glutathione and SAM synthesis, inhibiting homocysteine 
remethylation, increasing SAH and reducing hepatic choline and its 
precursors that could lead to liver damage (Pajares, et al; 1992). Requirements 
of folate are increased in obese NAFLD patients in whom the methionine 
cycle fails even in early stages of liver injury. Serum folate increases in these 
patients as a protective mechanism. Serum folate levels are inversely 
proportional to the body mass index in NAFLD patients and there is a positive 
correlation between serum total homocysteine levels and fat mass (Sandra 
Hirsch, et al; 2002). Folate supplementation in pharmacological doses (5mg 
daily) reduce the level of serum homocysteine significantly and increases the 
serum total antioxidant capacity, thereby reduces the risk of cardiovascular 
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diseases in adults with hypercholesterolemia than when compared with 
lovastatin (Shidfar F, et al; 2002).  
 
 
Homocysteine in liver transplant recipients 
Liver transplant recipients have an increased risk for cardiovascular disease 
because of a high incidence of obesity, arterial hypertension, diabetes 
mellitus, hyperlipidemia and hyperhomocysteinemia. Hyperhomocystinemia 
is associated with increased serum creatinine levels and renal dysfunction, 
and it is a frequent finding in liver transplant recipients. Treatment with folic 
acid 10 mg/day in liver transplant recipients, may reduce fasting serum total 
homocysteine levels (Herroro JI, et al; 2000).  Treatment with the folic acid 
metabolite L-5-methyl tetrahydrofolate in a dose of 1 mg per day, effectively 
reduces the serum total homocysteine level in orthoptic liver transplantation 
recipients (Akoglu B, et al; 2008). 
Homocysteine in cirrhosis 
In cirrhosis patients multiple metabolic abnormalities have been detected, 
including higher level of serum homocysteine, lower level of serum folate, 
lower level of vitamin B12, increase in serum copper and decrease in zinc 
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levels. A significant increase in endothelial markers are also seen in chronic 
liver disease, like thrombomodulin, fibrinogen and von Willibrand factor, 
while a fall in the level of vitamin K dependant factors (as prothrombin 
complex, protein C, protein S) and factors synthesized in  liver antithrombin 
are seen in cirrhosis. Hyperhomocysteinemia, a known atherogenic and 
thrombogenic risk factor not only increases cardiovascular morbidity and 
mortality, but also induces hepatic fibrosis and cirrhosis (Halifeoglu I, et al; 
2004). It has been suggested that the major metabolic block in the methionine 
catabolic pathway in cirrhotics exists at the level of the enzyme S-
adenosylmethionine synthetase because in previous studies using 
conventional amino-acid analyzers, no intermediates of 
transmethylation/transsulfuration were found to accumulate in plasma 
downstream of S-adenosylmethionine synthesis. Recent studies provide 
indirect evidence for two hitherto unrecognized alterations of methionine 
metabolism in cirrhotics, i.e. impairment of the transsulfuration of 
homocysteine at the level of cystathionine degradation and a shift in 
remethylation of homocysteine towards the betaine-homocysteine-
methyltransferase reaction. The serum levels of methionine, N,N-
dimethylglycine, N-methylglycine, cystathionine, and homocysteine were 
significantly higher in patients at Child stages B/C cirrhosis (Look MP, et al; 
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2000). Higher levels of serum homocysteine are more prominently seen in 
alcoholic cirrhosis patients, while increase in serum homocysteine levels is 
also present in non alcoholic cirrhosis patients (Bosy-Westphal A, et al., 
2003).  
 
 
Assessing severity of cirrhosis 
 
 
To understand the expected lifespan, perioperative mortality and fitness for 
liver transplantation, scoring systems have been developed to assess the 
severity of cirrhosis. Child-Turcotte-Pugh score, MELD score and MELD-Na 
score are the most commonly accepted scores to asses the severity of 
cirrhosis. 
 
Child-Turcotte-Pugh score 
 
The Child-Turcotte-Pugh (CTP) score, originally developed for the 
assessment of the outcome of patients with cirrhosis and portal hypertension, 
was extended for general prognosis, and to stratify patients on the waiting list 
for liver transplantation. Five variables serum bilirubin, serum albumin, 
Prothrombin time elevation or INR, ascites and encephalopathy are 
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considered, and a score of between 1 and 3 is accordingly assigned to each of 
these factors depending on the severity as given in the table below.  
Measure 1 Point 2 Points 3 Points 
Total bilirubin, μmol/l, (mg/dl) <34, (<2) 34-50, (2-3) >50, (>3) 
Serum albumin, g% >3.5 2.8-3.5 <2.8 
INR <1.7 1.71-2.20 > 2.20 
Ascites None Mild Severe 
Hepatic encephalopathy None Grade I-II  Grade III-IV 
 
Some older reference works substitute PT prolongation for INR. The sum of 
the scores provides the Child-Turcotte-Pugh score, which corresponds to a 
Child-Turcotte-Pugh grade of A, B or C (Child CG, et al; 1964). CTP grade A 
includes patients with scores of 5 and 6, CTP grade B includes patients with 
scores 7,8 and 9 while CTP grade C comprises patients with scores of 10 to 
15. This grading is used as a general means to verify the prognosis of the 
patient. For example, it can be used to determine the risk to a patient with 
regard to possible surgery, and also, to suggest the perceived survival of the 
patient over a period of time. Pharmaceutical manufacturers may use the 
Child-Pugh grade to suggest dose reductions, or to contraindicate the use of 
the drug, dependent on the degree of dysfunction of the cirrhotic liver. The 
use of CTP in prioritizing potential liver transplant recipients is limited by 
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several factors: the variables, ascites and encephalopathy, are all subjective 
and are influenced by medical therapy. The lack of an assessment of renal 
function, which is a reliable prognostic marker in cirrhosis, is an additional 
limiting factor. 
In primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC), 
the bilirubin references are changed to reflect the fact that these diseases 
feature high conjugated bilirubin levels. The upper limit for 1 point is 68 
μmol/l (4 mg/dl) and the upper limit for 2 points is 170 μmol/l (10 mg/dl). 
The survival rates in each CTP grades without liver transplantation are as 
follows. 
Points  Grade One year survival Two year survival 
    5-6    A           100%             85% 
    7-9    B             81%             57% 
10-15    C             45%             35% 
 
MELD Score 
MELD was originally developed at the Mayo Clinic, and at that point was 
called the "Mayo End-stage Liver Disease" score. It was derived in a series of 
patients undergoing TIPS procedures. The original version also included a 
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variable based on the underlying etiology of the liver disease (Wiesner RH, 
Malinchoc M, et al; 2000). A modification of this score was developed to 
predict mortality in patients with cirrhosis of different etiologies and 
severities of liver disease (Kamath PS, et al; 2001). This MELD score was 
found to be superior to the CTP score in predicting 3-months mortality and 
therefore the MELD score was implemented in 2002 in the United States for 
the prioritization of liver transplantation recipients. 
The MELD score has the advantage that it is based on a multivariable analysis 
of objective tests for serum bilirubin, INR and serum creatinine. Compared to 
CTP score, it also includes assessment of renal function, another major 
marker of the severity of the disease. Though serum bilirubin, creatinine, and 
INR are usually considered objective and therefore highly reliable, they may 
also be influenced by therapeutic manipulations, not only by disease 
progression. So, one important advantage of MELD, namely the 
independence of the subjective judgment by a clinician, is counterbalanced in 
part by arbitrary laboratory values.  
MELD uses the patient's values for serum bilirubin, serum creatinine, and the 
international normalized ratio for prothrombin time (INR) to predict survival. 
It is calculated according to the following formula:  
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MELD = 3.78[Loge serum bilirubin (mg/dL)] + 11.2[Loge INR] + 
9.57[Loge serum creatinine (mg/dL)] + 6.43 
 
If the patient has been dialyzed twice within the last 7 days, then the value for 
serum creatinine used should be 4.0. Any value less than one is given a value 
of 1 (i.e. if bilirubin is 0.8, a value of 1.0 is used) to prevent the occurrence of 
scores below 0 (the natural logarithm of 1 is 0, and any value below 1 would 
yield a negative result). MELD score represents a continuous variable ranging 
from 6 to 40.  
MELD score also proved to be a reliable marker of 1-year and 5-year survival 
across a broad spectrum of liver diseases including alcoholic cirrhosis and 
alcoholic hepatitis. In addition, MELD score has been shown to be a good 
prognostic marker in cases of variceal bleeding, spontaneous bacterial 
peritonitis, and hepatorenal syndrome (Chalasani N, et al; 2002). Independent 
of the cause of cirrhosis, high MELD score was shown to be associated with a 
decrease in residual liver function as measured by monoethylglycinexylidine 
test.  
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In interpreting the MELD Score in hospitalized patients, the three month 
mortality is as follows: 
• MELD score  > 40  — 71.3% mortality 
• MELD score 30–39 — 52.6% mortality 
• MELD score 20–29 — 19.6% mortality 
• MELD score 10–19 — 6.0% mortality 
• MELD score  <9     — 1.9% mortality 
Lab Test Frequency 
MELD score greater than or equal to 25; Lab testing needed every 7 days. 
MELD score 24-19; Lab testing needed every 30 days.  
MELD score 18-11; Lab testing needed every 90 days.  
MELD score less than or equal to 10; Lab testing needed every year. 
There are four Special Case Exceptions that will be assigned a higher MELD 
score than that assigned by the patient’s laboratory test results - 
Hepatocellular Carcinoma, Hepatopulmonary Syndrome, Primary Oxaluria 
and Familial Amyloidosis. 
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MELD – Na 
It was felt that patients with refractory ascites, normal creatinine, and 
preserved hepatic function could be under-scored with MELD. In particular, it 
was shown that persistent ascites and low serum sodium identified a subset of 
patients with relatively low MELD score (below 21) and a high risk of early 
death. During cirrhosis, hyponatremia results from solute-free water retention. 
Systemic arterial vasodilation leads to the release of antidiuretic hormone 
which, in turn, induces dilution hyponatremia. The activation of these 
mechanisms correlates with the degree of portal hypertension. 
Several studies have shown that hyponatremia is a strong predictor of early 
mortality, independent of MELD score. Changes in survival are especially 
pronounced for sodium concentrations ranging from 120 to 135 mEq/L. 
Within this range, a decrease in serum sodium of 1 mEq/L corresponds to a 
12% decrease in 3-month probability of survival. A modified score including 
serum sodium, termed MELD-Na, has been proposed as an alternative to 
MELD score.  
MELD Na = MELD – Na – (0.0025 x MELD x (140 - Na) + 140 (where the 
serum sodium concentration is between 125 and 140 mmol/L) (Kim WR, et 
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al; 2008). The accuracy of MELD-Na was shown to be slightly superior to 
that of MELD in candidates for transplantation. The effect of hyponatremia is 
higher in patients with low MELD score compared with those with high 
MELD score.  
A limitation to the incorporation of serum sodium into MELD is that during 
cirrhosis, marked changes in serum sodium concentration can result from 
several factors, including the administration of diuretics and intravenous 
hypotonic fluids. For example, the administration of diuretics leads to a 4 
mEq/L decrease in serum sodium, on average. In some patients the decrease 
may reach 10 mEq/L. In contrast, the use of V2-receptor antagonists for 
treating refractory ascites is encouraging. These agents induce a significant 
increase in serum sodium. 
In patients receiving anticoagulation therapy, like Budd-Chiary syndrome and 
cirrhosis with portal vein thrombosis, the INR is hardly interpretable to use in 
the calculation of MELD score. In these cases MELD-XI (MELD excluding 
INR) is a good scoring method. 
Patients with a rapid increase in MELD over time might be expected to have a 
worse outcome than those with stable or even decreasing MELD score. Delta 
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MELD is defined as the difference between current MELD and the lowest 
MELD measured within 30 days prior to current MELD, and was shown to be 
predictive of early mortality in patients with cirrhosis on univariate analysis 
(Forman LM, et al; 2001). 
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AIM OF THE STUDY  
 
 
To study fasting serum homocysteine level in patients with alcoholic cirrhosis 
and viral cirrhosis and to assess the serum homocysteine level as a prognostic 
marker by comparing the homocysteine level with MELD score and Child-
Turcotte-Pugh score. 
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MATERIALS AND METHODS 
 
Place of study     : Department of Digestive Health and Diseases, 
         Government peripheral hospital, Anna nagar, 
         Chennai. 
Type of study     : Prospective study. 
Period of study     : December 2009 to April 2011. 
Collaborating Department : Department of Biochemistry,  
                                              Kilpauk medical college,Kilpauk, Chennai. 
Ethical committee     : Approval obtained. 
Consent     : Informed consent obtained from all participants. 
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Selection of patients 
Fifty patients with alcoholic liver cirrhosis and fifteen cases of viral cirrhosis 
who satisfied the following inclusion criteria and not having any of the 
exclusion criteria were selected for the study. 
Inclusion criteria 
1) All cases of viral markers negative alcoholic cirrhosis of liver 
with portal hypertension and ascites, were included in the study. 
2) All cases of liver cirrhosis with portal hypertension and ascites 
due to chronic Hepatitis B or chronic Hepatitis C, of both sexes, 
without any history of alcohol intake were included in the study. 
Exclusion criteria 
1) Patients with both alcohol intake and viral marker positivity were 
excluded from the study. 
2) Alcoholic hepatitis or viral chronic hepatitis patients without any 
clinical signs of cirrhosis were not included. 
3) NASH, NAFLD were excluded. 
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4) Adult patients above 60 years of age were excluded to minimize 
the effect of old age on serum homocysteine level. 
5) Patients with diabetes mellitus, chronic renal failure, 
hypothyroidism, inflammatory bower disease and malabsorptive 
conditions were excluded from the study to avoid confounding 
effect on homocysteine level. 
6) Patients taking drugs like phenytoin, methotrexate, levodopa, 
fenofibrate, metformin, sulfasalazine and pyrimethamine were 
also excluded from the study. 
 
Study method 
 
 
Patient characteristics like age, sex and body mass index were noted. Detailed 
history from the patients regarding abdominal pain, abdominal distension, 
swelling of legs, reduced urine out put, yellowish discolouration of urine or 
eyes, fatigue, vomiting, vomiting of blood, passing black tarry stools, altered 
sleep pattern, altered sensorium, breathlessness and chestpain were taken. 
Any similar problem in the past and whether he is a known case of diabetes, 
hypertension, coronary heart disease, hypercholesterolemia, epilepsy, 
intestinal tuberculosis, previous jaundice, any previous abdominal surgeries 
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and details of the drugs he was taking so far, were asked in detail and noted. 
Detailed history regarding alcohol intake like brand of alcohol, quantity per 
day and duration of intake were asked. Similarly history regarding his 
smoking habits was recorded. Detailed history regarding his dietary pattern 
including vegetarian, non vegetarian food items and coffee intake was asked. 
History regarding the patients day to day physical exercise activities was also 
asked and recorded. 
 
Clinical examination 
 
Detailed general examination of the patient was done with regard to 
orientation to place, person and time, fever, pallor, icterus, pedal edema, 
clubbing, cyanosis, nutritional status, and lymphadenopathy. Vital signs were 
recorded for all patients. Clinical examination for cardiorespiratory status, 
flapping tremor and any neurological deficit were looked for. Thorough 
clinical examination of abdominal system was made out, particularly for the 
clinical signs of chronic liver disease, signs of portal hypertension, signs of 
hepatic encephalopathy and other complications of chronic liver disease, and 
clinical response to diuretics. 
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Investigations 
 
Urine examination for albumin, sugar, deposits, bile salts and bile pigments 
was done. Complete blood count including hemoglobin, total count, 
differential count, platelet count and PCV were recorded. Patient’s blood 
group was noted. Routine investigations like erythrocyte sedimentation rate, 
blood sugar, urea, creatinine, electrolytes - Na+, K+, Cl and HCO3- , were 
taken. Liver function tests total bilirubin, direct and indirect bilirubin, SGOT, 
SGPT, Alkaline Phosphatase, GGT, Total protein, Albumin, Globulin and 
Albumin / Globulin ratio were recorded. Prothrombin time (test & control) 
and INR value were noted. X-ray Chest and ECG were taken for all patients. 
Ultrasound abdomen was done for assessing liver size, echotexture, liver 
nodules, portal vein diameter, collaterals of portal hypertension, spleen size, 
splenic vein diameter and ascites. UGI endoscopy was done for all patients to 
look for esophageal or gastric varices, portal hypertensive gastropathy, gastric 
antral vascular ectasia, gastric or duodenal ulcers or any UGI bleed. Ascitic 
fluid analysis was done for protein, albumin, sugar, cell count and cytology. 
SAAG was calculated. Serum Homocysteine level in the morning fasting 
sample on the next day of admission, was estimated. Child-Turcotte-Pugh 
score was calculated for all patients, and using readymade calculator for 
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MELD score available in internet, MELD score was calculated for all 
patients. 
 
Study approach 
 
Patients with clinical signs of cirrhosis and portal hypertension of specific 
etiology either alcohol or viral, were selected for estimation of fasting serum 
homocysteine level. Fifty alcoholic cirrhosis and fifteen viral cirrhosis 
patients were enrolled for the study. Severity of cirrhosis was assessed for all 
the patients using Child-Turcotte-Pugh score and MELD score. The fasting 
serum homocysteine level was compared with both Child-Turcotte-Pugh and 
MELD scores. 
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RESULTS  
Demography 
All patients in alcoholic cirrhosis group are males (50 out of 50). 
Male : Female ratio in viral cirrhosis patients is 6 : 9 
Age group for alcoholic cirrhosis patients ranged from 29 to 60 years of 
age, and the mean age is 47.45 years. 
Age group for viral cirrhosis patients ranged from 39 to 60 years of age 
and the mean age is 47.8 years. 
 
Serum Homocysteine 
 
Mean serum homocysteine level in alcoholic cirrhosis patients is 23.4 
μmol/L. 
Maximum value for serum homocysteine is 45.39 μmol/L and the 
minimum value is 12.41 μmol/L in alcoholic cirrhosis patients. 
Number of alcoholic cirrhosis patients with serum homocysteine level 
more than the upper limit of normal value of 15 μmol/L is 41 out of 50 
patients (82%). 
 43 
Mean serum homocysteine level in viral cirrhosis patients is 10.05 
μmol/L. 
Maximum value for serum homocysteine is 15.21 μmol/L and 
minimum value is 7.24 μmol/L in viral cirrhosis patients. 
Number of viral cirrhosis patients with serum homocysteine level more 
than the upper limit of normal value of 15 μmol/L is 1 out of 15 patients 
(6.67%). 
 
Child – Turcotte – Pugh score 
Mean CTP score for alcoholic cirrhosis patients is 8.36, maximum CTP 
score is 14 and minimum score is 6. 
Mean CTP score for viral cirrhosis patients is 9.2, maximum CTP score 
is 13 and minimum score is 6. 
 
MELD score 
Mean MELD score for alcoholic cirrhosis patients is 12.22, maximum 
MELD score is 28 and minimum MELD score is 6. 
Mean MELD score for viral cirrhosis patients is 14.93, maximum 
MELD score is 26 and minimum MELD score is 7. 
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Correlation of CTP and MELD scores 
In alcoholic cirrhosis and viral cirrhosis patients, using Pearson correlation, 
the significance of CTP and MELD scores is calculated and the p value for 
this correlation is highly significant, p = 0.0001. 
 
Correlation of serum homocysteine with CTP and MELD scores 
The serum homocysteine levels correlate well with CTP and MELD scores 
when computed using the Pearson calculation, in both alcoholic and viral 
cirrhosis patients, and the p value for the significance is 0.0001, in both the 
groups. 
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STATISTICAL ANALYSIS 
All analyses are performed using SPSS 16.0 (SPSS Inc. Chicago, IL). 
 
Table: Descriptive Statistics 
Group     N Minimum Maximum Mean Standard
Deviation
Alcoholic group 
Homocysteine 
50     12.41     45.39 23.3996 7.91171 
CTP score 50       6     14   8.3600 2.43914 
MELD score 50       6     28 12.2200 5.96004 
Viral group 
Homocysteine 
15       7.24     15.21 10.0527 2.75191 
CTP score 15       6     13   9.2000 2.42605 
MELD score 15       7     26 14.9333 6.40833 
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Independent samples test 
 
Table: Levene’s test for Equality of variances 
 
 
Variable 
Levene’s test for 
Equality of variances 
      F Significance 
Homocysteine 10.661 0.002 
CTP score   0.120 0.730 
MELD score   0.467 0.497 
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Table: t – test for Equality of Means 
 
 
 
Variable 
 t – test for Equality of Means 
t df Sig 
2tailed 
Mean  
differ 
Std 
Error 
differ 
95% confidence 
Interval of the 
difference 
Lower Upper 
Homocy
steine 
Equal 
variance 
assumed 
 
Equal 
variance 
not 
assumed 
6.388 
 
 
 
 
10.07 
63 
 
 
 
 
61.49 
0.0001 
 
 
 
 
0.0001 
13.347 
 
 
 
 
13.347 
2.089 
 
 
 
 
1.325 
9.1717 
 
 
 
 
10.697 
17.522 
 
 
 
 
15.997 
CTP 
score 
Equal 
variance 
assumed 
 
Equal 
variance 
not 
assumed 
-1.17 
 
 
 
 
 
-1.17 
63 
 
 
 
 
 
23.17 
0.246 
 
 
 
 
 
0.252 
-0.840 
 
 
 
 
 
-0.840 
0.717 
 
 
 
 
 
0.715 
-2.273 
 
 
 
 
 
-2.318 
0.5932 
 
 
 
 
 
0.6387 
MELD 
score 
Equal 
variance 
assumed 
 
Equal 
variance 
not 
assumed 
-1.52 
 
 
 
 
 
-1.46 
63 
 
 
 
 
 
21.79 
0.133 
 
 
 
 
 
0.158 
-2.713 
 
 
 
 
 
-2.713 
1.785 
 
 
 
 
 
1.857 
-6.279 
 
 
 
 
 
-6.566 
0.8532 
 
 
 
 
 
1.1398 
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Table: Correlation of serum homocysteine with CTP and MELD scores 
Group Variable Method CTP 
score 
MELD 
score 
Alcohol Homocysteine 
(N=50) 
Pearson 
Correlation 
 
Significance (p) 
(2tailed) 
0.878* 
 
 
0.0001 
 
0.845* 
 
 
0.0001 
Viral Homocysteine 
(N=15) 
Pearson 
Correlation 
 
Significance (p) 
(2tailed) 
0.903* 
 
 
0.0001 
0.882* 
 
 
0.0001 
 
* correlation is significant at the 0.01 level (2 tailed). 
The ‘p’ value for serum homocysteine level compared with CTP score and 
MELD scores in both alcoholic cirrhosis and viral cirrhosis patients is 0.0001.  
 
Table: Correlation of CTP score with MELD score 
Group Variable Method MELD 
score
Alcohol CTP score 
(N=50) 
Pearson 
Correlation 
 
Significance (p) 
(2tailed) 
0.921 * 
 
 
0.0001 
Viral CTP score 
(N=15) 
Pearson 
Correlation 
 
Significance (p) 
(2tailed) 
0.966* 
 
 
0.0001 
 
* correlation is significant at the 0.01 level (2 tailed). 
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The ‘p’ value for CTP score compared with MELD score in both alcoholic 
cirrhosis and viral cirrhosis patients is 0.0001. 
 
Hence, the serum homocysteine level highly correlates with both CTP score 
and MELD score in both alcoholic cirrhosis and viral cirrhosis patients and 
hence indicates the severity of liver cirrhosis. 
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DISCUSSION 
Studies in cultured hepatocytes suggest a role of the liver in metabolism of 
homocysteine. In fact, hyperhomocysteinaemia has been reported in several 
experimental models of liver damage (Garcia-Tevijano ER, Ferre N, et al; 
2002). Chronic treatment with ethanol or CCl4 in experimental animals is 
associated with hyperho-mocysteinaemia, and the hepatoprotective effect of 
S-adenosyl-methionine on experimental cirrhosis is accompanied by a 
normalization of methionine metabolism and a decrease in homocysteine 
concentration (Ferre N, et al; 2002). However, the presence and degree of 
hyperhomocysteinaemia in patients with liver disease is, as yet, not well 
defined. 
 
In a study at King George’s medical university, Lucknow, India, in 2005, 
comprising of 30 patients with cirrhosis of liver, including 12 alcoholic and 
18 non alcoholic cirrhosis, serum homocysteine levels were found to be 
elevated in 68% cases. The serum homocysteine levels were significantly 
elevated in chronic liver disease cases compared to controls, to 13.44 + 8.09 
μmol/L (p < 0.001). The levels were significantly elevated in alcoholic 
cirrhosis patients to 23.04 + 10.67 μmol/L, compared to non alcoholics (10.78 
+ 4.22 μmol/L), p value < 0.001. 
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In Portugal study, the serum homocysteine levels in chronic alcoholics were 
found to be 21.2 + 8.0 μmol/L, twice as high as controls with a p value of 
0.05 (Marilia L Cravo, et al; 1996).  
 
In another study at England, hyperhomocysteinemia (concentration > 12 
mmol//l) was stated in 70% of the alcoholic cirrhosis patients and mean 
homocysteine concentration was statistically significantly higher if compared 
to the controls (13.29 +  8.16 vs 8.03 + 1.6 μmol/L, p < 0.05) (Kazimierska E, 
et al; 2003). 
 
In one study at Slovak republic, a statistically significant increase of serum 
homocysteine was seen in all groups of patients with chronic liver diseases: 
steatosis 12.1 + 7.3, (p < 0.01), mild fibrosis/cirrhosis, 14.1 + 10.8, (p < 0.01), 
up to severe cirrhosis, 16.9 + 10.9, (p < 0.001), (Anna Remkova, Milan 
Remko, et al; 2009). 
 
Forty three biopsy proven cirrhosis patients of different etiology were studied 
at France in 2001 and the results were: 74% of the patients had elevated 
plasma homocysteine levels defined as >13.4 μmol/L (mean+2SD of healthy 
age matched controls). Increased plasma homocysteine concentrations were 
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seen in alcoholic as well as in non-alcoholic cirrhotics (Anja Bosy-Westphal, 
et al; 2001). But in the present study, serum homocysteine levels were 
significantly elevated in alcoholic cirrhosis patients (82%) than in non 
alcoholic viral cirrhosis patients (6.67%). 
 
In a study at United States of America, including 40 alcoholic cirrhosis 
patients, 26 active alcohol drinkers without clinical evidence of liver disease 
and 28 healthy controls, the median homocysteine level in alcoholic cirrhosis 
patients was 10.2 μmol/L, with a range of 5.4 to 58.3 μmol/L. The median 
homocysteine level in active alcohol drinkers was 8.8 μmol/L, with a range of 
5.8 to 23 μmol/L, and in the healthy controls the median value was 6.4 
μmol/L, with a range of 4.1 to 10 μmol/L, in the same study. The p value for 
increase in homocysteine level was < 0.0001 in both alcoholic cirrhosis and 
active alcohol drinkers when compared with healthy controls (Valentina 
Medici, et al; 2010). In the same study, the elevation in homocysteine level 
when compared with CTP and MELD scores, the p values were 0.041 and 
0.02 respectively. 
 
In the present study, serum homocysteine levels are elevated more than the 
upper limit of normal (15 μmol/L) in 41 out of 50 (82%) alcoholic cirrhosis 
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patients compared to only one patient out of 15 (6.67%) viral cirrhosis 
patients. The average serum homocysteine level in alcoholic group is 23.4 + 
7.91 μmol/L compared to 10.05 + 2.75 μmol/L in viral cirrhosis group. The 
‘p’ value for variation in serum homocysteine level corresponding to CTP and 
MELD scores is < 0.0001 in both alcoholic and viral cirrhosis patients. But 
the ‘p’ value can be taken as significant, only in alcoholic cirrhosis patients, 
as there is only one patient with elevated homocysteine level in the viral 
cirrhosis group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54 
CONCLUSION 
 
1) Serum homocysteine levels are significantly elevated in alcoholic 
cirrhosis patients (82%). 
2) Serum homocysteine levels are not significantly elevated in viral 
cirrhosis patients (6.67%). 
3) Serum homocysteine levels correlated significantly with CTP and 
MELD scores in both alcoholic cirrhosis and viral cirrhosis patients. 
4) Fasting serum homocysteine level may be used as a prognostic marker 
in alcoholic cirrhosis patients. 
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APPENDIX B 
 
MASTER CHART FOR ALCOHOLIC CIRRHOSIS PATIENTS 
S.No Name of the 
patient 
Age/ 
Sex 
Serum 
Biliru 
bin 
Serum 
Albumin 
Serum 
Creatinine
INR Ascites
 
Ence 
phalo 
pathy 
CTP
score
MELD
score 
Serum 
Homo 
cysteine 
  1 Mohammed 48/M 2.1 3.3 0.8 1.54 Mild Nil 8 12 30.08
  2 Parthiban 38/M 17.6 2.2 1.1 2.01 Severe Gr3 14 26 27.91
  3 Devaraj 50/M 2.3 3.4 1.0 1.48 Mild Nil 8 14 14.97
  4 Suresh 36/M 17.8 3.4 1.2 2.14 Severe Gr3 13 28 45.39
  5 Kannappan 55/M 1.4 3.7 0.8 1.23 Mild Nil 6 8 14.65
  6 Kumaresan 49/M 7.8 2.5 1.2 1.58 Severe Gr3 13 21 32.43 
  7 Kuppan 44/M 3.2 2.7 1.2 1.48 Mild Nil 10 17 29.31
  8 Rajagopal 56/M 11.7 3.3 1.0 1.33 Mild Nil 9 19 28.32
  9 Panneerselvam 54/M 4.3 3.6 0.9 1.26 Mild Nil 8 14 27.61
10 Ramkumar 39/M 2.3 3.7 0.8 1.23 Mild Nil 7 10 23.56 
11 Munusamy 43/M 3.4 3.2 0.9 1.28 Mild Gr1 10 13 27.10
12 Kumarimuthu 29/M 0.8 3.9 0.6 1.20 Mild Nil 6 6 16.92
13 Anandhan 33/M 2.7 3.4 0.8 1.26 Mild Nil 8 11 19.73 
14 Venkatesan 45/M 4.2 2.9 0.9 1.54 Severe Gr1 11 16 33.57
15 Gurujikannappan 60/M 5.4 2.7 1.3 1.64 Severe Gr1 12 21 38.12 
16 Rajkumar 49/M 2.2 3.2 0.7 1.26 Mild Nil 8 9 22.83
17 Balan 56/M 1.2 3.7 0.8 1.30 Mild Nil 6 8 14.24 
18 Govindhan 50/M 0.9 3.3 0.7 1.17 Mild Nil 7 6 18.47
19 Ramadoss 42/M 1.3 2.6 0.8 1.08 Mild Nil 8 6 17.40 
20 Devadoss 47/M 0.9 2.7 0.8 1.13 Mild Nil 8 6 20.83
21 Jayakumar 55/M 1.1 3.1 0.7 1.30 Mild Nil 7 6 22.61
22 Sivakumar 50/M 2.2 3.4 1.0 1.43 Mild Gr1 9 13 20.32
23 Ramanathan 40/M 1.4 3.7 0.7 1.32 Mild Nil 6 7 16.94 
24 Saravanan 38/M 5.9 2.5 1.3 1.83 Severe Gr3 14 22 42.16
25 Kumar 42/M 3.8 3.1 1.1 1.50 Mild Gr1 10 17 31.18
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S.No Name of the 
patient 
Age/ 
Sex 
Serum 
Biliru 
bin 
Serum 
Albumin 
Serum 
Creatinine
INR Ascites
 
Ence 
phalo 
pathy 
CTP
score
MELD
score 
Serum 
Homo 
cysteine 
26 Kanniappan 43/M 1.5 2.2 0.9 1.41 Mild Nil 8 11 18.71
27 Vijayakumar 38/M 0.6 3.6 0.6 1.10 Mild Nil 6 6 12.41
28 Pachiappan 60/M 0.8 3.7 0.9 1.16 Mild Nil 6 6 13.90
29 Raja 55/M 1.8 3.2 0.9 1.31 Mild Nil 7 11 18.12 
30 Kuppan 44/M 3.2 2.7 1.2 1.46 Mild Nil 10 17 29.31
31 Rajagopal 56/M 1.7 3.3 1.0 1.32 Mild Nil 7 12 18.32 
32 Panneerselvam 54/M 1.3 3.6 0.9 1.26 Mild Nil 6 9 17.61
33 Kumaresan 49/M 7.8 2.5 1.2 1.71 Severe Gr2 13 22 32.43 
34 Vellaiappan 45/M 1.2 3.5 0.9 1.23 Mild Nil 7 8 19.22
35 Muthukumar 39/M 1.4 3.7 0.8 1.35 Mild Nil 6 9 14.57 
36 Gopinath 44/M 3.9 3.1 1.2 1.49 Mild Gr1 10 18 25.31
37 Raghuram 54/M 1.8 3.5 1.0 1.26 Mild Nil 7 11 22.10 
38 Sathyaseelan 45/M 1.3 3.7 0.8 1.24 Mild Nil 6 8 14.57
39 Kandhasamy 40/M 0.9 3.6 0.7 1.16 Mild Nil 6 6 13.28
40 Kumaravel 58/M 1.1 3.4 0.8 1.20 Mild Nil 7 7 19.57
41 Anandhm 60/M 7.7 2.5 1.4 1.76 Severe Gr1 13 24 37.18
42 Thirumaran 52/M 1.3 3.6 0.9 1.10 Mild Nil 6 7 14.75
43 Arokiyasamy 60/M 2.4 3.2 0.9 1.17 Mild Nil 8 10 21.33
44 Selvam 47/M 6.6 2.7 1.3 1.35 Severe Gr1 12 19 36.84
45 Anbuselvan 39/M 1.4 3.8 0.7 1.13 Mild Nil 6 6 21.13
46 Kumarimuthu 55/M 2.4 3.3 0.8 1.16 Mild Nil 8 9 24.58 
47 Sundaram 52/M 1.5 3.5 0.7 1.22 Mild Nil 7 7 23.12
48 Loganathan 47/M 1.3 3.6 0.9 1.31 Mild Nil 6 9 19.87
49 Savarimuthu 41/M 2.7 3.6 1.0 1.23 Mild Nil 7 13 20.94
50 Balakumar 53/M 1.9 3.2 0.8 1.30 Mild Nil 7 10 24.16 
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MASTER CHART FOR VIRAL CIRRHOSIS PATIENTS 
 
S.No Name of the 
patient 
Age/ 
Sex 
Serum
Biliru 
bin 
Serum 
Albumin
Serum 
Creatinine
INR Ascites 
 
Ence 
phalo
pathy
CTP
score
MELD
score 
Serum 
Homo 
cysteine
  1 Amaresan 41/M 1.8 2.7 0.9 1.52 Mild Nil 8 9 9.23 
  2 Karthikeyan 44/M 13.6 2.2 1.3 1.91 Severe Gr1 13 26 13.41 
  3 Jeyarani 56/F 2.5 3.4 0.9 1.48 Mild Nil 8 13 7.97
  4 Surendran 39/M 7.8 3.3 1.2 1.98 Severe Gr1 12 24 15.21
  5 Kanniammal 54/F 1.3 3.6 0.8 1.23 Mild Nil 6 8 8.45
  6 Vijayalaxmi 39/F 7.9 2.5 1.3 1.54 Severe Gr1 12 22 11.68 
  7 Kuppammal 44/F 3.3 2.7 1.1 1.45 Mild Nil 10 16 9.35
  8 Rajaguru 55/M 6.7 3.3 1.0 1.26 Mild Nil 9 16 8.42
  9 Anandhavalli 52/F 3.7 3.7 0.8 1.30 Mild Nil 8 12 7.46
10 Ravikumar 47/M 2.6 3.6 0.8 1.17 Mild Nil 7 10 8.35
11 Venkatesh 41/M 7.2 2.6 1.4 1.54 Severe Gr1 12 22 13.56
12 Sivakami 60/F 4.4 2.7 1.3 1.64 Severe Gr1 12 20 14.15
13 Rajakumari 45/F 2.4 3.1 0.8 1.26 Mild Nil 8 10 8.84
14 Bakyam 50/F 1.3 3.6 0.9 1.30 Mild Nil 6 9 7.24
15 Govindhammal 50/F 1.4 3.3 0.8 1.17 Mild Nil 7 7 7.47 
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APPENDIX A 
PROFORMA 
Name of the patient :                      S.No : 
 
Age / Sex  : 
 
IP No   : 
 
DDHD No  : 
 
Presenting symptoms : Abdominal pain, abdominal distension, swelling of legs, reduced 
urine out put, yellowish discolouration of urine or eyes, fatigue, 
vomiting, vomiting of blood, passing black tarry stools, altered 
sleep pattern, altered sensorium, breathlessness, 
 
Past H / O similar problem before 
 
Past H / O  : DM, HT, TB, COPD, CAHD, Chronic drug intake, Abdominal 
surgery,   Jaundice   
 
Personal history : Diet, Smoking, Alcohol (brand, quantity, duration) 
 
General examination : BMI:  Orientation / Fever / Pallor / Icterus / Pedal edema /   
Clubbing / Cyanosis / Lymphadenopathy / Others 
 
 
Vital signs  : Pulse rate:  BP:  Resp.rate:    Temp: 
 
Abdomen  : 
 
 
 
 
Signs of CLD  : 
 
 
 
CVS   : 
 
RS   : 
 
CNS   : 
 
 x
Investigations 
 
Urine    : Alb -   Sugar -  Dep -   BS -   BP –  
 
CBC   : Hb -  TC -   DC -   Platelet -  PCV – 
 
ESR   :     Blood group: 
 
Blood   : Sugar -  Urea -   Creatinine –  
 
Electrolytes  : Na+ -  K+ -   Cl-  HCO3- -  
 
LFT   : Total bilirubin -   Direct -  Indirect –  
 
    SGOT -  SGPT -  Alk.Phos - GGT –  
 
    Total protein -  Albumin -  Globulin –  
 
Prothrombin time : Test -  Control -   INR -  
 
X-Ray Chest  :       
 
ECG : 
 
USG abdomen  : 
 
 
 
 
UGI endoscopy  : 
 
 
Ascitic fluid  : Protein -   Albumin -   Sugar -  Cell count –  
 
    Cytology -   Others -   
 
SAAG    : 
 
Serum Homocysteine  : 
 
MELD score   : 
 
Child-Turcotte-Pugh score :  
